| human | Q5 |
| P2287 | CRIStin ID | 21635 |
| P496 | ORCID iD | 0000-0002-5785-802X |
| P2038 | ResearchGate profile ID | Tom_Mollnes |
| P214 | VIAF ID | 5341149108590068780000 |
| P10832 | WorldCat Entities ID | E39PBJdrFrqxTM8TDjgQ3rp3wC |
| P27 | country of citizenship | Norway | Q20 |
| P108 | employer | University of Oslo | Q486156 |
| P734 | family name | Mollnes | Q122837677 |
| Mollnes | Q122837677 | ||
| Mollnes | Q122837677 | ||
| P735 | given name | Tom | Q3354498 |
| Tom | Q3354498 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q90340810 | 'Stealth' corporate innovation: an emerging threat for therapeutic drug development |
| Q99556971 | A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity |
| Q63728167 | A New Model for Evaluation of Biocompatibility: Combined Determination of Neoepitopes in Blood and on Artificial Surfaces Demonstrates Reduced Complement Activation by Immobilization of Heparin |
| Q41585201 | A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases |
| Q83586244 | A helicopter flight does not induce significant changes in systemic biomarker profiles |
| Q74010979 | A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s |
| Q40007131 | A new dynamic porcine model of meningococcal shock |
| Q74028378 | A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo |
| Q53842724 | A novel method for direct measurement of complement convertases activity in human serum. |
| Q37458908 | A parameter for IL-10 and TGF-ß mediated regulation of HIV-1 specific T cell activation provides novel information and relates to progression markers |
| Q68996815 | A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9 |
| Q38231108 | A vital role for complement in heart disease |
| Q33618032 | Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality |
| Q46157681 | Activation of coagulation and platelets by candidate membranes of implantable devices in a whole blood model without soluble anticoagulant |
| Q63728214 | Activation of complement during apheresis |
| Q42626734 | Activation of complement, kallikrein-kinin, fibrinolysis and coagulation systems by urinary catheters. Effect of time and temperature in biocompatibility studies. |
| Q35684979 | Activation of polymorphonuclear leukocytes by candidate biomaterials for an implantable glucose sensor |
| Q71268881 | Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema |
| Q71653261 | Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema |
| Q38204335 | Activation-dependent antigenic changes of human C3. |
| Q38204339 | Activation-dependent epitopes in the terminal complement pathway. |
| Q48500144 | Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock |
| Q71731360 | Adhesion molecule expression and complement activation in vessel walls in synovial tissue from patients with chronic inflammatory joint disease |
| Q37888017 | Advances in assay of complement function and activation |
| Q59791600 | Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population |
| Q112713082 | Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood |
| Q34881427 | Albumin lavage does not improve the outcome of meconium aspiration syndrome |
| Q38675415 | Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. |
| Q39772079 | Alginate microbeads are complement compatible, in contrast to polycation containing microcapsules, as revealed in a human whole blood model |
| Q51434339 | Alginate microsphere compositions dictate different mechanisms of complement activation with consequences for cytokine release and leukocyte activation. |
| Q40780546 | Alterations in the terminal complement pathway in leukopenic children with malignant diseases during episodes with evidence of infection |
| Q40753393 | Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation |
| Q83838557 | Alternative pathway activation of complement in laparoscopic and open rectal surgery |
| Q77218657 | An ex vivo perfusion model to evaluate hyperacute rejection in a discordant pig-to-human combination |
| Q38115914 | An international serum standard for application in assays to detect human complement activation products |
| Q92706192 | Analysis of cytokines |
| Q77579690 | Anti-TNF treatment of baboons with sepsis reduces TNF-alpha, IL-6 and IL-8, but not the degree of complement activation |
| Q41393053 | Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity |
| Q96160627 | Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential? |
| Q45874143 | Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation |
| Q35610543 | Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor |
| Q89347975 | Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus |
| Q42940112 | Arginine catabolic mobile element is associated with low antibiotic resistance and low pathogenicity in Staphylococcus epidermidis from neonates |
| Q44956353 | Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition |
| Q35069163 | Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person |
| Q33750678 | Assessments of skin and tongue microcirculation reveals major changes in porcine sepsis |
| Q34676160 | Association of ficolin-3 with severity and outcome of chronic heart failure |
| Q90272859 | Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism |
| Q27693290 | Atrial fibrillation: inflammation in disguise? |
| Q42551631 | Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass |
| Q90664000 | Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development |
| Q100501025 | Avoiding ambient air in test tubes during incubations of human whole-blood minimizes complement background activation |
| Q82993437 | Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery |
| Q63728255 | Biocompatibility of Urinary Catheters. Effect on Complement Activation |
| Q61624632 | Biocompatibility of candidate materials for an implantable glucose sensor in terms of complement and neutrophil activating properties |
| Q63728216 | Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits |
| Q63728208 | Biocompatibility of white cell filters as evaluated by complement activation |
| Q43407892 | Biomarker profile in off-pump and on-pump coronary artery bypass grafting surgery in low-risk patients |
| Q92511385 | Biphasic Release of the Alarmin High Mobility Group Box 1 Protein Early After Trauma Predicts Poor Clinical Outcome |
| Q58840336 | Body composition and plasma levels of inflammatory biomarkers in COPD |
| Q73283114 | Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo |
| Q38042218 | Bride and groom in systemic inflammation--the bells ring for complement and Toll in cooperation |
| Q48294349 | Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes |
| Q57808232 | C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release |
| Q47191457 | C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction |
| Q72379866 | C1 inhibitor and diagnosis of hereditary angioedema in newborns |
| Q73668439 | C1-inhibitor attenuates human serum induced E-selectin expression of pig aortic endothelial cells |
| Q40805518 | C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model |
| Q40667554 | C1-inhibitor efficiently delays clot development in normal human whole blood and inhibits Escherichia coli-induced coagulation measured by thromboelastometry |
| Q44198286 | C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood |
| Q44242656 | C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping |
| Q34388554 | C1-inhibitor: an anti-inflammatory reagent with therapeutic potential |
| Q63728223 | C3 Activation Products, C3 Containing Immune Complexes, the Terminal Complement Complex and Native C9 in Patients with Rheumatoid Arthritis |
| Q70877531 | C3 is activated in hereditary angioedema, and C1/C1-inhibitor complexes rise during physical stress in untreated patients |
| Q45307986 | C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes. |
| Q35565857 | CD14 and complement crosstalk and largely mediate the transcriptional response to Escherichia coli in human whole blood as revealed by DNA microarray |
| Q33694581 | CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs |
| Q101566209 | CD14 inhibition improves survival and attenuates thrombo-inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis |
| Q40106379 | CD59 efficiently protects human NT2-N neurons against complement-mediated damage |
| Q60249832 | COMP-C3b Complexes in Rheumatoid Arthritis with Severe Extraarticular Manifestations |
| Q63728194 | Calprotectin and complement activation during major operations with or without cardiopulmonary bypass |
| Q40269162 | Candidate inhibitors of porcine complement |
| Q71571523 | Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility |
| Q91653737 | Changes in cytokines during treatment of elderly, hospitalized psychiatric patients - a naturalistic study |
| Q51591969 | Changes in laboratory variables in rheumatoid arthritis patients during a trial of fasting and one-year vegetarian diet. |
| Q46632063 | Changes in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndrome |
| Q80722859 | Changes in the cytokine network and complement parameters during open heart surgery |
| Q63728267 | Characterization of a Monoclonal Antibody MoAb bH6 Reacting with a Neoepitope of Human C3 Expressed on C3b, iC3b, and C3c |
| Q38299548 | Characterization of natural human anti-non-gal antibodies and their effect on activation of porcine gal-deficient endothelial cells |
| Q77318897 | Characterization of soluble terminal complement complex assembled in C8beta-deficient plasma and serum |
| Q39092541 | Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation |
| Q100570058 | Choice of immunoassay to evaluate porcine cytokine levels |
| Q63727982 | Cholesterol Crystals Activate the Lectin Complement Pathway via Ficolin-2 and Mannose-Binding Lectin: Implications for the Progression of Atherosclerosis |
| Q91592466 | Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor |
| Q44956209 | Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF. |
| Q37700323 | Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release |
| Q99413492 | Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis |
| Q86919807 | Chronic fatigue syndrome/myalgic encephalo-myelitis--pathophysiology, diagnosis and treatment |
| Q54551355 | Circulating cell-free DNA is elevated in community-acquired bacterial pneumonia and predicts short-term outcome. |
| Q60949495 | Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome |
| Q85564932 | Clinical experience with microdialysis catheters in pediatric liver transplants |
| Q39657040 | Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation |
| Q52372103 | Combined Inhibition of C5 and CD14 Attenuates Systemic Inflammation in a Piglet Model of Meconium Aspiration Syndrome. |
| Q37003067 | Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex. |
| Q37668330 | Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis |
| Q50912775 | Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. |
| Q54420024 | Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. |
| Q52647705 | Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by Staphylococcus aureus in a human whole blood model. |
| Q40892746 | Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis |
| Q43540341 | Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis |
| Q43155175 | Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response |
| Q51634558 | Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery. |
| Q91543116 | Comparison of cytokine changes in three different lipoprotein apheresis systems in an ex vivo whole blood model |
| Q51213213 | Comparison of in vitro and in vivo complement activation by metal and bioabsorbable screws used in anterior cruciate ligament reconstruction. |
| Q77781834 | Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices |
| Q41226485 | Complement Activation Correlates With Disease Severity and Contributes to Cytokine Responses in Plasmodium falciparum Malaria |
| Q58143863 | Complement Activation Reflects Severity of Meconium Aspiration Syndrome in Newborn Pigs |
| Q90173708 | Complement Activation in 22q11.2 Deletion Syndrome |
| Q35049546 | Complement C3 and C5 deficiency affects fracture healing |
| Q45178548 | Complement C5a is a key mediator of meconium-induced neutrophil activation |
| Q92623099 | Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood |
| Q63728210 | Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials |
| Q40883151 | Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide |
| Q51302706 | Complement activation and cytokine and chemokines release during mediastinitis. |
| Q79779998 | Complement activation and cytokine response by BioProtein, a bacterial single cell protein |
| Q69075766 | Complement activation and endotoxin levels in systemic meningococcal disease |
| Q44746430 | Complement activation and plasma levels of C4b-binding protein in critical limb ischemia patients |
| Q74429124 | Complement activation and release of interleukin-6 and tumour necrosis factor-alpha in drained and systemic blood after major orthopaedic surgery |
| Q54015134 | Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. |
| Q92672348 | Complement activation assessed by the plasma terminal complement complex and future risk of venous thromboembolism |
| Q59139208 | Complement activation by Pseudomonas aeruginosa biofilms |
| Q70837875 | Complement activation by angiographic catheters in vitro |
| Q61624629 | Complement activation by candidate biomaterials of an implantable microfabricated medical device |
| Q40520440 | Complement activation by cholesterol crystals triggers a subsequent cytokine response |
| Q63728272 | Complement activation by extracorporeal circulation: effects of precoating a membrane oxygenator circuit with human whole blood |
| Q80628854 | Complement activation by neutrophil granulocytes |
| Q61624635 | Complement activation by proposed biomaterials intended for composition of a glucose sensor |
| Q53985301 | Complement activation during and after open-heart surgery is only marginally affected by the choice of fluid for volume replacement. |
| Q43916730 | Complement activation during cardiopulmonary bypass: comparison between the use of large volumes of plasma and dextran 70. |
| Q72902802 | Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits |
| Q68819551 | Complement activation during major operations with or without cardiopulmonary bypass |
| Q68830216 | Complement activation following multiple injuries |
| Q86868173 | Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery |
| Q44419254 | Complement activation in early protocol kidney graft biopsies after living-donor transplantation1 |
| Q47831976 | Complement activation in experimental human malaria infection |
| Q77291319 | Complement activation in injured patients occurs immediately and is dependent on the severity of the trauma |
| Q40684844 | Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment |
| Q73115068 | Complement activation in patients with systemic lupus erythematosus without nephritis |
| Q69539307 | Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex |
| Q63728196 | Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC) |
| Q77537486 | Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant |
| Q42674523 | Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome |
| Q33416830 | Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission |
| Q63728229 | Complement activation with bubble and membrane oxygentors in aortocorpnary bypass grafting |
| Q33372177 | Complement analysis in clinic and research |
| Q34674625 | Complement analysis in the 21st century |
| Q43628501 | Complement analysis tests |
| Q34911214 | Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis |
| Q36750470 | Complement and coagulation: strangers or partners in crime? |
| Q70792851 | Complement and granulocyte activation in two different types of heparinized extracorporeal circuits |
| Q63916932 | Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4 |
| Q92755379 | Complement component C3 and the TLR co-receptor CD14 are not involved in angiotensin II induced cardiac remodelling |
| Q37680021 | Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function |
| Q97071813 | Complement in Sepsis - when Science meets Clinics |
| Q39347118 | Complement in clinical medicine: Clinical trials, case reports and therapy monitoring |
| Q58524210 | Complement in inflammatory tissue damage and disease |
| Q33389544 | Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis |
| Q61624627 | Complement inhibition prevents granulocyte activation caused by candidate biomaterials for an implantable microfabricated device |
| Q83531020 | Complement profile and activation mechanisms by different LDL apheresis systems |
| Q71089527 | Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic |
| Q71452534 | Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation |
| Q58524435 | Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts |
| Q90181424 | Corrigendum to "Changes in cytokines during treatment of elderly, hospitalized psychiatric patients-A naturalistic study" [Psychoneuroendocrinology, 108C (2019), 135-139] |
| Q33613839 | Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies |
| Q81502003 | Cyanobacterial LPS antagonist (CyP)-a novel and efficient inhibitor of Escherichia coli LPS-induced cytokine response in the pig |
| Q38601679 | Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation |
| Q34682109 | Cytokine network in adults with falciparum Malaria and HIV-1: increased IL-8 and IP-10 levels are associated with disease severity |
| Q59128496 | Cytokine profiles and diagnoses in elderly, hospitalized psychiatric patients |
| Q91217173 | Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases |
| Q48240599 | Cytokine responses, microbial aetiology and short-term outcome in community-acquired pneumonia |
| Q37228094 | Cytokine secretion depends on Galalpha(1,3)Gal expression in a pig-to-human whole blood model |
| Q45808316 | Cytokines monitored by microdialysis detect rejection earlier than current methods in liver transplantation. |
| Q82780778 | Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections |
| Q63728178 | Deposition of C3, the terminal complement complex and vitronectin in primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34392163 | Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon |
| Q63728275 | Deposits of terminal complement complex and S-protein on follicular dendritic cells in human lymphoid tissue |
| Q63728067 | Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions |
| Q70601636 | Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay |
| Q35091378 | Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics |
| Q48539766 | Dexamethasone reduces bilirubin-induced toxicity and IL-8 and MCP-1 release in human NT2-N neurons |
| Q71346271 | Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit |
| Q51751160 | Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery. |
| Q43238266 | Different inflammatory responses induced by three LDL-lowering apheresis columns |
| Q69591172 | Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro |
| Q45285014 | Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production |
| Q37938954 | Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood |
| Q70799716 | Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems |
| Q43094753 | Dissecting the effects of lipopolysaccharides from nonlipopolysaccharide molecules in experimental porcine meningococcal sepsis |
| Q39729995 | Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice |
| Q28077955 | Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets |
| Q73175440 | Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study |
| Q83622372 | Early bedside detection of ischemia and rejection in liver transplants by microdialysis |
| Q48128522 | Early protective effect of hypothermia in newborn pigs after hyperoxic, but not after normoxic, reoxygenation |
| Q41733922 | Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn |
| Q42425232 | Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo |
| Q38727268 | Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses |
| Q94016562 | Editorial: The Role of Complement in Health and Disease |
| Q48168132 | Effect of Perfusion Fluids on Recovery of Inflammatory Mediators in Microdialysis. |
| Q40242030 | Effect of acidosis on IL-8 and MCP-1 during hypoxia and reoxygenation in human NT2-N neurons |
| Q44781829 | Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation |
| Q74242637 | Effect of filtration and storage of platelet concentrates on the production of the chemotaxins C5a, interleukin 8, tumor necrosis factor alpha, and leukotriene B4 |
| Q93553158 | Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro |
| Q48523684 | Effect of perfusion temperature on the inflammatory response during pediatric cardiac surgery |
| Q58523732 | Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement |
| Q50172275 | Effect of syringe-assisted liposuction on activation of cascade systems and circulating cells when using the superwet or tumescent technique. |
| Q38736170 | Effect of the anticoagulant, storage time and temperature of blood samples on the concentrations of 27 multiplex assayed cytokines - Consequences for defining reference values in healthy humans |
| Q72096048 | Effect of time, temperature and additives on a functional assay of C1 inhibitor |
| Q46412470 | Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation |
| Q74045510 | Effect of whole and fractionated intravenous immunoglobulin on complement in vitro |
| Q37725357 | Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report |
| Q47934724 | Effects of Natural versus Synthetic Surfactant with SP-B and SP-C Analogs in a Porcine Model of Meconium Aspiration Syndrome |
| Q91711993 | Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts |
| Q70047504 | Effects of methylprednisolone on complement activation and leukocyte counts during cardiopulmonary bypass |
| Q73485378 | Effects on Complement, Granulocytes and Platelets of a Leukocyte-Depletion Filter During in vitro Extracorporeal Circulation |
| Q54520263 | Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard. |
| Q93123835 | Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis |
| Q99708092 | Elevated plasma sTIM-3 levels in severe Covid-19 patients |
| Q63728235 | Elutable factors from latex-containing materials activate complement and inhibit cell proliferation. An in vitro biocompatibility study of medical devices |
| Q92276301 | Endotoxin Removal in Septic Shock with the Alteco® LPS Adsorber was Safe But Showed No Benefit Compared to Placebo in the Double-Blind Randomized Controlled Trial - the Asset Study |
| Q41951549 | Enzyme immunoassay detection of circulating immune complexes by monoclonal antibodies to C3 neoepitopes with special reference to IgG concentration and to interfering anti-immunoglobulin antibodies |
| Q42152239 | Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. |
| Q44102024 | Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation |
| Q44811967 | Ethical aspects of xenotransplantation |
| Q38501306 | European Union funded project on the development of a whole complement deficiency screening ELISA-A story of success and an exceptional manager: Mohamed R. Daha |
| Q70833514 | Ex vivo model for xenotransplantation |
| Q30405122 | Excessive innate immune response and mutant D222G/N in severe A (H1N1) pandemic influenza |
| Q44777046 | Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome |
| Q55499462 | Exploration of 27 plasma immune markers: a cross-sectional comparison of 64 old psychiatric inpatients having unipolar major depression and 18 non-depressed old persons. |
| Q79372112 | Expression of complement regulators and receptors on human NT2-N neurons--effect of hypoxia and reoxygenation |
| Q35833465 | Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease) |
| Q73329336 | Extracorporeal membrane oxygenation using a centrifugal pump and a servo regulator to prevent negative inlet pressure |
| Q33819173 | Ficolins do not alter host immune responses to lipopolysaccharide-induced inflammation in vivo |
| Q70227757 | Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin |
| Q51547298 | Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. |
| Q30488438 | Gene expression profiling of Gram-negative bacteria-induced inflammation in human whole blood: The role of complement and CD14-mediated innate immune response |
| Q38621308 | Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy |
| Q80544185 | Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies |
| Q52724383 | Granulocyte and monocyte CD11b expression during plasma separation is dependent on complement factor 5 (C5) - an ex vivo study with blood from a C5-deficient individual. |
| Q100518584 | Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency |
| Q42921502 | Hematologic and hemostatic changes induced by different columns during LDL apheresis |
| Q67900766 | Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex |
| Q41760427 | Heparin-coated cardiopulmonary bypass circuits selectively deplete the pattern recognition molecule ficolin-2 of the lectin complement pathway in vivo |
| Q74652222 | Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population |
| Q74652227 | Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo |
| Q52009791 | Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. |
| Q35552728 | Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency |
| Q41137641 | High MIP-1β Levels in Plasma Predict Long-Term Immunological Nonresponse to Suppressive Antiretroviral Therapy in HIV Infection |
| Q71487401 | High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes |
| Q41869537 | High doses of corticosteroids in total hip replacement. Effects on components of coagulation, fibrinolytic, plasma kallikrein-kinin and complement systems. |
| Q44968212 | High ficolin-3 level at the time of transplantation is an independent risk factor for graft loss in kidney transplant recipients |
| Q34637905 | High frequency and intensity of drinking may attenuate increased inflammatory cytokine levels of major depression in alcohol-use disorders |
| Q43249094 | High mobility group box-1 protein--one step closer to the clinic? |
| Q59812665 | High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections |
| Q39765481 | High serum CXCL10 in Rickettsia conorii infection is endothelial cell mediated subsequent to whole blood activation |
| Q77318931 | High-dose intravenous immunoglobulin treatment activates complement in vivo |
| Q81251776 | Hirudin versus heparin for use in whole blood in vitro biocompatibility models |
| Q38563385 | Human Endothelial Cell Activation by Escherichia coli and Staphylococcus aureus Is Mediated by TNF and IL-1β Secondarily to Activation of C5 and CD14 in Whole Blood. |
| Q71613839 | Human complement activation by polygeline and dextran 70 |
| Q53619438 | Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation. |
| Q37320731 | Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature |
| Q77440133 | Human serum-induced expression of E-selectin on porcine aortic endothelial cells in vitro is totally complement mediated |
| Q44117365 | Human serum-induced porcine endothelial cell E-selectin expression is associated with IgG3 and IgM anti-Gal antibodies |
| Q37331701 | Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. |
| Q58746571 | IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction |
| Q41536733 | IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy |
| Q74371550 | Identification of a C-->T mutation in the reactive-site coding region of the C1-inhibitor gene and its detection by an improved mutation-specific polymerase chain reaction method |
| Q69047388 | Identification of a human C5 beta-chain epitope exposed in the native complement component but concealed in the SC5b-9 complex |
| Q68568728 | IgG and IgA subclass distribution of total immunoglobulin and rheumatoid factors in rheumatoid tissue plasma cells |
| Q72658160 | IgG subclass distribution and complement activation ability of autoantibodies to neutrophil cytoplasmic antigens (ANCA) |
| Q63728151 | Immobilized heparin inhibits the increase in leukocyte surface expression of adhesion molecules |
| Q47886246 | Immunoglobulin prolongs survival of pig kidneys perfused ex vivo with human blood |
| Q42484954 | Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae |
| Q69457654 | Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology |
| Q43736762 | Impact of the complement lectin pathway on cytomegalovirus disease early after kidney transplantation |
| Q91529047 | Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency |
| Q46084621 | In vitro evaluation of PHISIO-coated sets for pediatric cardiac surgery |
| Q74600601 | In vitro evaluation of new surface coatings for extracorporeal circulation |
| Q63728237 | Increased Amounts of C4-Containing Immune Complexes and Inefficient Activation of C3 and the Terminal Complement Pathway in a Patient with Homozygous C2 Deficiency and Systemic Lupus Erythematosus |
| Q93161214 | Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis |
| Q110220761 | Increased Interleukin-6 and Macrophage Chemoattractant Protein-1 are associated with Respiratory Failure in COVID-19 |
| Q48273912 | Increased Levels of Interferon-Inducible Protein 10 (IP-10) in 22q11.2 Deletion Syndrome |
| Q48714746 | Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention |
| Q110220758 | Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19 |
| Q45143112 | Increased plasma levels of the terminal complement complex in patients with evidence of complement activation. |
| Q73588794 | Increased systemic activation of neutrophils but not complement in preeclampsia |
| Q34983608 | Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis |
| Q31010163 | Inflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet Trial |
| Q64107051 | Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study |
| Q84531122 | Inflammatory markers sampled by microdialysis catheters distinguish rejection from ischemia in liver grafts |
| Q81065355 | Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis |
| Q61624624 | Inflammatory response induced by candidate biomaterials of an implantable microfabricated sensor |
| Q51661938 | Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. |
| Q63728170 | Inhibition of Complement-Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding Properties |
| Q41293387 | Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis |
| Q37075440 | Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood |
| Q73157644 | Inhibition of platelet aggregation by the GPIIb/IIIa antagonist reopro does not significantly prolong xenograft survival in an ex vivo model |
| Q37480055 | Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis |
| Q53378010 | Interactions of histidine-rich glycoprotein with immunoglobulins and proteins of the complement system. |
| Q51672778 | Interleukin-6 may predict survival in extracorporeal membrane oxygenation treatment. |
| Q89367585 | Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction |
| Q89533105 | Intestinal epithelial cells express immunomodulatory ISG15 during active ulcerative colitis and Crohn's disease |
| Q93203980 | Intestinal inflammatory profile shows increase in a diversity of biomarkers in irritable bowel syndrome |
| Q68995673 | Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex |
| Q70819406 | Intrathecal immune response in neonatal Flavobacterium meningosepticum meningitis |
| Q90803796 | Iron oxide nanoparticles enhance Toll-like receptor-induced cytokines in a particle size- and actin-dependent manner in human blood |
| Q33739773 | Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model |
| Q92225218 | Key role of the number of complement receptor 1 on erythrocytes for binding of Escherichia coli to erythrocytes and for leukocyte phagocytosis and oxidative burst in human whole blood |
| Q51284720 | LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response. |
| Q38016475 | LDL apheresis and inflammation--implications for atherosclerosis |
| Q44761311 | Latex gloves as a cause of inflammation and eczema |
| Q86848793 | Letter to editor |
| Q77767820 | Leucocyte filtration during cardiopulmonary bypass hardly changed leucocyte counts and did not influence myeloperoxidase, complement, cytokines or platelets |
| Q77781831 | Leucocyte filtration during cardiopulmonary reperfusion in coronary artery bypass surgery |
| Q49241621 | Low Levels of Immunoglobulins and Mannose-Binding Lectin Are Not Associated With Etiology, Severity, or Outcome in Community-Acquired Pneumonia |
| Q36168197 | Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients |
| Q34544169 | Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex. |
| Q81633506 | Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation |
| Q79255657 | Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction |
| Q43664563 | Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy |
| Q39942876 | Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock |
| Q40949279 | Massive Organ Inflammation in Experimental and in Clinical Meningococcal Septic Shock |
| Q35137245 | Measurement of complement activation |
| Q42605147 | Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair |
| Q46297372 | Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood |
| Q58143875 | Meconium Is a Potent Activator of Complement in Human Serum and in Piglets |
| Q47827294 | Meconium aspiration syndrome induces complement-associated systemic inflammatory response in newborn piglets. |
| Q38365665 | Meconium aspiration syndrome: possible pathophysiological mechanisms and future potential therapies |
| Q39749376 | Meconium-induced release of cytokines is mediated by the TRL4/MD-2 complex in a CD14-dependent manner |
| Q63728242 | Methylprednisolone in High Doses Gives Different Effects on the Early and the Late Part of Complement |
| Q40296283 | Microdialysis for monitoring inflammation: efficient recovery of cytokines and anaphylotoxins provided optimal catheter pore size and fluid velocity conditions |
| Q46301554 | Microdialysis monitoring of liver grafts by metabolic parameters, cytokine production, and complement activation |
| Q45336533 | Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria meningitidis-exposed whole blood |
| Q35579838 | Modern complement analysis |
| Q73327228 | Modest release of adipsin/factor D by liposuction when using the superwet or tumescent technique |
| Q58524417 | Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model |
| Q81542969 | Modulatory effect of mannose-binding lectin on cytokine responses: possible roles in HIV infection |
| Q43762567 | Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma |
| Q39003418 | Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease |
| Q39396085 | Multiorgan procurement increases systemic inflammation in brain dead donors |
| Q91035814 | NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies |
| Q35186384 | Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood |
| Q43056315 | Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. |
| Q40094023 | New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs |
| Q84132906 | Occupational exposure to bacterial single cell protein induces inflammation in lung and blood |
| Q47986979 | Off-pump cardiac surgery abolishes complement activation |
| Q41247465 | Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. |
| Q35987250 | Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans |
| Q51747182 | Pathway-specific complement activity in pigs evaluated with a human functional complement assay. |
| Q83286444 | Patient tolerance regarding different low-density lipoprotein apheresis columns: frequent minor side effects and high patient satisfaction |
| Q40293658 | Patients with depression display cytokine levels in serum and cerebrospinal fluid similar to patients with diffuse neurological symptoms without a defined diagnosis |
| Q43263010 | Perfusion temperature, thyroid hormones and inflammation during pediatric cardiac surgery |
| Q90557433 | Perioperative Infusion of Glucagon-Like Peptide-1 Prevents Insulin Resistance After Surgical Trauma in Female Pigs |
| Q69199289 | Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence |
| Q84588520 | Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment |
| Q35197936 | Perspectives on complement in xenotransplantation |
| Q63916921 | Phagocytosis of live and dead Escherichia coli and Staphylococcus aureus in human whole blood is markedly reduced by combined inhibition of C5aR1 and CD14 |
| Q33937506 | Pig endogenous retrovirus--a threat to clinical xenotransplantation? |
| Q40538984 | Plasma IP-10 Is Increased in Immunological NonResponders and Associated With Activated Regulatory T Cells and Persisting Low CD4 Counts |
| Q40454558 | Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients. |
| Q36330303 | Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases |
| Q48392820 | Plasma cytokine expression in adolescent chronic fatigue syndrome |
| Q63728264 | Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins |
| Q92905413 | Plasma levels of mannose-binding lectin and future risk of venous thromboembolism |
| Q88497588 | Plasma n-6 Polyunsaturated Fatty Acid Levels and Survival in Renal Transplantation |
| Q73013567 | Platelet compatibility of an artificial surface modified with functionally active heparin |
| Q40489320 | Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex |
| Q67899334 | Platelets and vitronectin: immunocytochemical localization and platelet interaction with exogenously added vitronectin |
| Q44262859 | Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs |
| Q35247803 | Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood |
| Q39894966 | Post-hypoxic hypothermia is protective in human NT2-N neurons regardless of oxygen concentration during reoxygenation |
| Q51662938 | Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. |
| Q48518025 | Prediction of inflammatory responses induced by biomaterials in contact with human blood using protein fingerprint from plasma |
| Q87230332 | Preface. 15th European Meeting on Complement in Human Disease 2015, Uppsala, Sweden |
| Q38112539 | Primary complement C5 deficiencies - molecular characterization and clinical review of two families |
| Q58524487 | Prolongation of ex vivo–perfused pig xenograft survival by the complement inhibitor compstatin |
| Q37612601 | Properdin binding to complement activating surfaces depends on initial C3b deposition |
| Q92202571 | Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions |
| Q63728269 | Quantification in Enzyme-Linked Immunosorbent Assay of a C3 Neoepitope Expressed on Activated Human Complement Factor C3 |
| Q63728232 | Quantification of Non-Activated (Native) Complement Component C9 Synthesized by Alveolar Macrophages from Patients with Sarcoidosis |
| Q68941679 | Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex |
| Q72072954 | Quantitation of vitronectin and clusterin. Pitfalls and solutions in enzyme immunoassays for adhesive proteins |
| Q35846217 | Reciprocal relationship between contact and complement system activation on artificial polymers exposed to whole human blood |
| Q46721795 | Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation |
| Q45004244 | Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient-a case report |
| Q43624185 | Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations |
| Q72145145 | Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass |
| Q47302043 | Reduced inflammatory response by transcatheter, as compared to surgical aortic valve replacement |
| Q39628216 | Regulation of complement |
| Q53988152 | Release of interleukin 6 and activation of complement during and after paediatric cardiopulmonary bypass. Effect of autotransfusion of shed mediastinal blood and ultrafiltration. |
| Q39741712 | Rickettsia conorii is a potent complement activator in vivo and combined inhibition of complement and CD14 is required for attenuation of the cytokine response ex vivo |
| Q60907689 | Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency |
| Q46734185 | Role of complement and CD14 in meconium-induced cytokine formation |
| Q74528573 | Role of complement in xenotransplantation |
| Q81862428 | Role of granulocytes and monocytes in the polyvinyl chloride-induced synthesis of interleukin 8, monocyte chemoattractant protein 1, and leukotriene B4 |
| Q72699703 | Roller and centrifugal pumps compared in vitro with regard to haemolysis, granulocyte and complement activation |
| Q45345182 | S protein binds to serum-treated agarose beads independently of complement activation and the formation of the terminal complement complex on the beads |
| Q69056443 | S-protein is synthesized by human monocytes and macrophages in vitro |
| Q91673125 | Selective and marked decrease of complement receptor C5aR2 in human thoracic aortic aneurysms: a dysregulation with potential inflammatory effects |
| Q44438073 | Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood |
| Q84982914 | Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia |
| Q33423884 | Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome |
| Q93075496 | Sepsis causes right ventricular myocardial inflammation independent of pulmonary hypertension in a porcine sepsis model |
| Q41335176 | Serum brain-derived neurotrophic factor levels in relation to comorbid depression and cytokine levels in Nepalese men with alcohol-use disorders |
| Q41208311 | Serum clusterin and vitronectin in alcoholic cirrhosis |
| Q46090548 | Serum cytokines and chronic fatigue in adults surviving after childhood leukemia and lymphoma |
| Q37401644 | Severe human septic shock involves more than tumor necrosis factor |
| Q88937328 | Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction |
| Q99254843 | Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement |
| Q81205152 | Soluble toll-like receptor 2 in HIV infection: association with disease progression |
| Q40790855 | Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis |
| Q36845133 | Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation |
| Q50045385 | Staphylococcus aureus-induced Complement Activation Promotes Tissue Factor-mediated Coagulation |
| Q85645912 | Staphylococcus epidermidis biofilms induce lower complement activation in neonates as compared with adults |
| Q82472259 | Staphylococcus epidermidis polysaccharide intercellular adhesin activates complement |
| Q44967045 | Statin drugs do not affect serum complement activation in vitro |
| Q36191361 | Strategies of therapeutic complement inhibition |
| Q63728257 | Studies on the Dose Dependence of Endotoxin-Induced in vitro Activation of the Complement System |
| Q86637273 | Study findings challenge the content validity of the Canadian Consensus Criteria for adolescent chronic fatigue syndrome |
| Q34025504 | Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis |
| Q34395719 | Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis |
| Q48462645 | Syndecan-1 plasma levels during coronary artery bypass surgery with and without cardiopulmonary bypass |
| Q41715510 | Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts |
| Q63728246 | Synthesis of Complement by Alveolar Macrophages from Patients with Sarcoidosis |
| Q63728261 | Synthesis of Soluble C3 and C9 Neoepitopes by Human Alveolar Macrophages in Vitro |
| Q39401125 | Systemic CD14 inhibition attenuates organ inflammation in porcine Escherichia coli sepsis |
| Q93191366 | Systemic Inflammation Persists the First Year After Mild Traumatic Brain Injury: Results from the Prospective Trondheim Mild TBI Study |
| Q34316549 | Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis |
| Q99564634 | Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients |
| Q51320785 | Systemic inflammation in acute intermittent porphyria: a case-control study. |
| Q84323166 | Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study |
| Q84738653 | Systemic mannose-binding lectin is not associated with Chronic Obstructive Pulmonary Disease |
| Q68441628 | Systemic meningococcal disease: a model infection to study acute endotoxinemia in man |
| Q41153717 | TLR8 Senses Staphylococcus aureus RNA in Human Primary Monocytes and Macrophages and Induces IFN-β Production via a TAK1-IKKβ-IRF5 Signaling Pathway |
| Q89825287 | TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria |
| Q69046813 | Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues |
| Q71684650 | Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid |
| Q63728182 | The B chain, but not the A chain, of Ricinus communis activates human complement |
| Q82275192 | The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelet Aggregation |
| Q47776991 | The Membrane Glycoprotein IIb/IIIa Complex Mediates Deposition of Thrombin-stimulated Blood Platelets on Polystyrene Plastic Under Static Conditions |
| Q59126052 | The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain |
| Q28295227 | The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon regulatory factor-3 on phagosomes |
| Q91089875 | The Role of Complement in Liver Injury, Regeneration, and Transplantation |
| Q40333926 | The alternative complement pathway is dysregulated in patients with chronic heart failure |
| Q37141297 | The alternative complement pathway revisited |
| Q39014623 | The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load |
| Q41809457 | The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent |
| Q39937519 | The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction |
| Q90634391 | The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment |
| Q28083548 | The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis |
| Q40530046 | The complement system in trauma-related and ischemic tissue damage: a brief review. |
| Q63728042 | The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification |
| Q43245640 | The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome |
| Q43475073 | The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood |
| Q71071247 | The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation |
| Q44462095 | The induction of cytokines by polycation containing microspheres by a complement dependent mechanism |
| Q73827760 | The inflammatory response following treatment of abdominal aortic aneurysms: a comparison between open surgery and endovascular repair |
| Q41072889 | The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood |
| Q81009325 | The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation |
| Q54352891 | The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. |
| Q52577998 | The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. |
| Q36564335 | The role of complement in biomaterial-induced inflammation |
| Q37341644 | The role of complement in meconium aspiration syndrome |
| Q42285785 | The role of properdin in zymosan- and Escherichia coli-induced complement activation |
| Q77567155 | The significance of heparin-coated veno-venous bypass circuits in liver transplantation |
| Q45851911 | The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis |
| Q92649970 | The synthetic antimicrobial peptide LTX21 induces inflammatory responses in a human whole blood model and a murine peritoneum model |
| Q69601882 | The terminal complement complex in sera deficient in the eighth component of complement (C8) |
| Q41675270 | The use of flow cytometry to detect the biosynthesis of complement components |
| Q26781190 | Therapeutic complement inhibition – from experimental to clinical medicine |
| Q83153148 | Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles |
| Q115649867 | Thrombin Differentially Modulates the Acute Inflammatory Response to Escherichia coli and Staphylococcus aureus in Human Whole Blood |
| Q63728206 | Time for new concepts about measurement of complement activation by cardiopulmonary bypass? |
| Q30391894 | Toward an injectable continuous osmotic glucose sensor |
| Q47107793 | Transforming growth factor beta (TGF-β) in adolescent chronic fatigue syndrome |
| Q47851292 | Transitions Between Circulatory States After Out-of-Hospital Cardiac Arrest: Protocol for an Observational, Prospective Cohort Study. |
| Q71612540 | Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model |
| Q92121586 | Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study |
| Q53989716 | Ultrafiltration after cardiopulmonary bypass in children: effects on hemodynamics, cytokines and complement. |
| Q73899766 | Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery |
| Q74314612 | Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model |
| Q47776684 | Vitronectin inhibits blood platelet aggregation |
| Q33686083 | Xenotransplantation: how to overcome the complement obstacle? |
| Q81462312 | [A programme for boosting medical research in North Norway, 1992-2001] |
| Q72010386 | [Angioedema associated with ACE inhibitors] |
| Q70878363 | [Reduced blood utilization in hip arthroplasty. Introduction of a blood preservation program] |
| Q56777199 | [Transplantation from animal to man] |
Search more.